Unexplained Anemia with Pyoderma Gangrenosum-Like Ulcer

  • Mohammad Ali El-Darouti
Chapter

Abstract

A 25-year-old female presented with an extensive ulceration of the left upper and lower eyelids (Fig. 40.1). Generally, she had pallor, fatigue and malaise. Her medical history was positive for autoimmune hepatitis.

Keywords

Fatigue Lymphoma Leukemia Anemia Methotrexate 

Bibliography

  1. Balduini CL, Guarnone R, Pecci A, Centenara E, Rosangela I, Ascari E. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica. 1999;84(12):16.Google Scholar
  2. Besa EC. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. Med Clin North Am. 1992;76(3):599–617.PubMedGoogle Scholar
  3. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.PubMedCrossRefGoogle Scholar
  4. Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. The FAB classi­fication (proposals) applied to bone marrow biopsy. Am J Clin Pathol. 1987;87:180–6.PubMedGoogle Scholar
  5. Goldberg H, Lusk E, Moore J, Nowell PC, Besa EC. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease. Cancer Res. 1990;50(21):6876–81.PubMedGoogle Scholar
  6. List AF, Garewal HS, Sandberg AA. The myelodysplastic syndromes, biology and implications for management. J Clin Oncol. 1990;8:1424–41.PubMedGoogle Scholar
  7. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.PubMedCrossRefGoogle Scholar
  8. Lübbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol. 2001;114(2):349–57.PubMedCrossRefGoogle Scholar
  9. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42.PubMedCrossRefGoogle Scholar
  10. Maschek H, Georgii A, Kaloutal V, et al. Myelofibrosis in primary myelodysplastic syndromes. A retrospective study of 352 patients. Eur J Haematol. 1992;48:208–14.PubMedCrossRefGoogle Scholar
  11. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Hoagland HC, Noel P. The 5q-syndrome. A single institution study of 43 consecutive cases. Blood. 1993;81:1040–5.PubMedGoogle Scholar
  12. Orazi A, Albitar M, Heerema NA, Haskins NS, Neiman RS. Hypoplastic myelodysplastic syndrome can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107:268–74.PubMedGoogle Scholar
  13. Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, Diez JL, Bureo E, Marqués ML, Arranz E, Ríos R, Martínez Climent JA, Vallespí T, Florensa L, Woessner S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108(2):346–56. doi: 2.PubMedCrossRefGoogle Scholar
  14. Tricot G, Vlietnick R, Boogaerts MA, Hendrickx B, De-Wolf-Peeters C, Van den Berghe H, et al. Prognostic factors in the myelodysplastic syndromes. Importance of initial data on peripheral blood counts, bone marrow, cytology, trephine biopsy and chromosomal analysis. Br J Haematol. 1985;60:19–32.PubMedCrossRefGoogle Scholar
  15. Vardiman JW. Myelodysplastic/myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.Google Scholar
  16. Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001a.Google Scholar
  17. Vardiman JW, Pierre R, Imbert M, Bain B, Brunning RD, Flandrin G. Juvenile myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001b.Google Scholar
  18. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956–62.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Mohammad Ali El-Darouti
    • 1
  1. 1.Cairo UniversityCairoEgypt

Personalised recommendations